Completed OBSERVATIONAL NCT03623347

Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment (TEMOBEVA)

Neo-adjuvant Treatment of Glioblastomas With Marked to Severe Neurological Impairment Using Upfront Bevacizumab/témozolomide Association Before an Eventual Radiotherapy. Multicentric Phase II Study

Sponsor: Centre Hospitalier Universitaire, Amiens

Conditions Chemoradiotherapy

Interventions TMZ and BEV induction before chemoradiotherapy

Updated 5 times since 2018 Last updated: Jun 6, 2023 Started: Jan 1, 2011 Primary completion: May 12, 2017 Completion: May 12, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Chemoradiotherapy, this trial is completed. The trial is conducted by Centre Hospitalier Universitaire, Amiens and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jul 2023 — Jul 2024 [monthly]

Completed
Jan 2021 — Jul 2023 [monthly]

Completed
Sep 2018 — Jan 2021 [monthly]

Completed

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire, Amiens

Data source: Centre Hospitalier Universitaire, Amiens

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.